肝胆癌生物标志物的研究进展
本文总结了肝细胞癌(HCC)和胆管癌(CCA)生物标志物的开发现状。HCC分子改变尚未转化为生物标志物,主要因缺乏可成药突变和高度异质性;CCA已识别多个治疗靶点,生物标志物驱动的治疗正在2/3期临床试验中评估。
要点
- HCC生物标志物开发受限于可成药突变缺乏和疾病异质性。
- CCA已发现多个治疗靶点,生物标志物驱动治疗进入2/3期试验。
- 生物标志物用于诊断、预后和预测治疗反应以改善患者分层。
核心结论
- HCC生物标志物开发尚未成功转化,CCA生物标志物驱动治疗正在临床试验中评估。
主要发现
- HCC多数缺乏可成药突变且异质性显著,阻碍生物标志物进展。
- CCA已识别多个治疗靶点,生物标志物驱动治疗处于2/3期评估。
临床怎么用
- 生物标志物可用于HCC和CCA的诊断、预后及治疗反应预测,优化患者分层。
局限性
- HCC分子改变尚未转化为生物标志物,主要因缺乏可成药突变和高度异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical management of primary liver cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) has significantly changed in the last 3 years. The introduction of systemic therapies, including immune-based therapies and biomarker-driven therapies, has significantly improved survival, particularly in patients at advanced stages of disease. Survival is still poor, and projections from the World Health Organization underscore the need to improve outcomes in these patients. Biomarkers have emerged as powerful tools for the diagnosis, prognosis, and prediction of treatment responses to improve patient stratification and maximize clinical benefits. Recent advances in understanding the molecular alterations of HCC have not yet translated into biomarkers. Some reasons for the lack of progress are the absence of druggable mutations in the majority of liver cancers and the significant heterogeneity of the disease. In contrast, several therapeutic targets have been identified in CCA, and biomarker-driven therapies are currently under evaluation in phase 2/3 clinical trials. Here, we summarize the status on biomarker development for HCC and CCA.
引用
- Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology. 2020. PMID: 32045030. doi:10.1002/hep.31175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。